The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma

J Surg Oncol. 2018 Sep;118(3):390-396. doi: 10.1002/jso.25164. Epub 2018 Aug 16.

Abstract

Background: This study was undertaken to determine the optimal thyroid-stimulating hormone (TSH) value associated with structural recurrence in patients with low-risk or intermediate-risk papillary thyroid carcinoma (PTC) who underwent thyroid lobectomy.

Methods: Patients with PTC (n = 1047) who received thyroid lobectomy and central compartment node dissection were included in the study.

Results: Structural recurrence occurred in 42 of the patients (4.0%), and no patient died of PTC. Multivariate analysis showed a primary tumor size (with a cut-off of 0.85 cm) and serum TSH level measured 1 year after the initial surgery (cut-off 1.85 mU/L) independently predicted structural recurrence.

Conclusions: TSH levels during the early postoperative period need to be monitored and maintained in the lower normal range even in patients with low- or intermediate-risk PTC undergoing thyroid lobectomy.

Keywords: low- and intermediate-ATA risk; papillary thyroid carcinoma; prognosis; thyroid lobectomy; thyroid-stimulating hormone.

MeSH terms

  • Biomarkers, Tumor / blood*
  • Carcinoma, Papillary / secondary
  • Carcinoma, Papillary / surgery*
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / blood*
  • Neoplasm Recurrence, Local / diagnosis
  • Postoperative Period
  • Prognosis
  • Risk Factors
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / surgery*
  • Thyroidectomy / methods*
  • Thyrotropin / blood*

Substances

  • Biomarkers, Tumor
  • Thyrotropin